Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome
Talha Badar(Mayo Clinic in Florida), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Aditya Shetty(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Hsiang‐Chun Chen(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), Carlos E. Bueso‐Ramos(The University of Texas MD Anderson Cancer Center)
Cited by 39
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k